跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 514 条关于
“Cabozantinib Ipsen”
全部
514
临床试验
288
药物
20
机构
18
资讯
188
去年
Scotland Approves New Cancer Treatments for Prostate and Liver Cancers
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
2年前
Cabozantinib/Atezolizumab Fails to Meet OS Endpoint in mCRPC, Regulatory Submissions Limited
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
去年
Ipsen Advances Pipeline with Multiple Regulatory Wins and Strategic Partnerships in 2024
2年前
Ipsen Discontinues Cabometyx Combination for Prostate Cancer After Phase III Failure
去年
Bylvay Shows Sustained Improvement in Itch and Bile Acid Levels in Rare Cholestatic Liver Diseases
去年
Cabozantinib Significantly Improves Progression-Free Survival in Advanced Neuroendocrine Tumors
2年前
Cabozantinib/Nivolumab Shows Consistent Benefits in RCC, Except for Favorable-Risk Group
第 1 页,共 19 页
上一页
下一页